WHAT IS CLAIMED IS:

1.   A method of reducing mammalian hair growth which comprises

selecting an area of skin from which reduced hair growth is desired; and

applying to said area of skin a dermatologically acceptable composition

comprising an agonist of prostaglandin DP-receptor in an amount effective to reduce hair

growth.

2.   The method of claim 1, wherein said agonist is a prostaglandin D_2 analog.

3.   The method of claim 1, wherein said agonist is a prostaglandin D_2 derivative.

4.   The method of claim 1, wherein said agonist interacts strongly with the

prostaglandin DP-receptor.

5.   The method of claim 1, wherein said agonist is 11-deoxy-11-methylene PGD_2.

6.   The method of claim 1, wherein said agonist is 15(R)-15-methyl PGD_2.

7.   The method of claim 1, wherein said agonist is (S)-15-methyl PGD_2.

8.   The method of claim 1, wherein said agonist is 15-deoxy-$\Delta^{12,14}$-PGD_2.

9.   The method of claim 1, wherein said agonist is 16,16-dimethyl-PGD_2.

10.   The method of claim 1, wherein said agonist is 17-phenyl trinor PGD_2.

11.   The method of claim 1, wherein said agonist is 9β-halogen-15-cyclohexyl-

prostaglandin.

12.   The method of claim 1, wherein said agonist is 11α-halogen-15-cyclohexyl-

prostaglandin.

13.   The method of claim 1, wherein said agonist is acetic acid, [[(2Z)-4-

[(1R,2R,3R,5R)-5-chloro-2-[(1E,3S)-3-cyclohexyl-3-L hydroxy-1-propenyl]-3-

hydroxycyclopentyl]-2-butenyl]oxy]- (9CI).

14.   The method of claim 1, wherein said agonist is butanoic acid, 4-

[(1R,2R,3S,6R)-2-[(3S)-3-cyclohexyl-3-hydroxy-1-propynyl]-3-

hydroxybicyclo[4.2.0]oct-7-ylidene]-, (4Z)- (9CI).

15.   The method of claim 1, wherein said agonist is butanoic acid, 4-

[(1S,2S,3R,6S)-2-[(3S)-3-cyclohexyl-3-hydroxy-1-propynyl]-3-

hydroxybicyclo[4.2.0]oct-7-ylidene]-, (4Z)- (9CI).

16.   The method of claim 1, wherein said agonist is 5-heptenoic acid, 7-[(1S,2S,3S,4R)-3-[(1E,3S)-3-cyclohexyl-3-hydroxy-1-propenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI).

17.   The method of claim 1, wherein said agonist is 5-heptenoic acid, 7-[(1R,2R,3R,5R)-5-chloro-2-[(1E,3S)-3-cyclohexyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-, (5Z)- (9CI).

18.   The method of claim 1, wherein said agonist is 4-imidazolidineheptanoic acid, 3-[(3R)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo-, (4S)-rel- (9CI).

19.   The method of claim 1, wherein said agonist is (4R)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid.

20.   The method of claim 1, wherein said agonist is benzoic acid, 4-[3-[3-[2-(1-hydroxycyclohexyl)ethyl]-4-oxo-2-thiazolidinyl]propyl]- (9CI).

21.   The method of claim 1, wherein said agonist is benzoic acid, 4-[3-[3-(3-hydroxyoctyl)-4-oxo-2-thiazolidinyl]propyl]- (9CI).

22.   The method of claim 1, wherein said agonist is 4-imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (9CI).

23.   The method of claim 1, wherein said agonist is a PGD_2 metabolite.

24.   The method of claim 1, wherein said agonist is 13, 14-dihydro-15-keto PGD_2.

25.   The method of claim 1, wherein said agonist is PGJ_2.

26.   The method of claim 1, wherein said agonist is Δ^{12}-PGJ_2.

27.   The method of claim 1, wherein said agonist is 15-deoxy-$\Delta^{12,14}$-PGJ_2.

28.   The method of claim 1, wherein said agonist is 9,10-dihydro-15-deoxy-$\Delta^{12,14}$-PGJ_2.

29.   The method of claim 1, wherein the concentration of said agonist in said composition is between 0.1% and 30%.

30.   The method of claim 1, wherein the composition provides a reduction in hair growth of at least 30% when tested in the Human Hair Follicle assay.

31.   The method of claim 1, wherein the composition provides a reduction in hair growth of at least 60% when tested in the Human Hair Follicle assay.

32.   The method of claim 1, wherein the agonist is applied to the skin in an amount of from 10 to 3000 micrograms of said agonist per square centimeter of skin.

33. The method of claim 1, wherein said mammal is a human.

34. The method of claim 33, wherein said area of skin is on the face of a human.

35. The method of claim 33, wherein the composition is applied to the area of skin in conjunction with shaving.

36. The method of claim 33, wherein said area of skin is on a leg of the human.

37. The method of claim 33, wherein said area of skin is on an arm of the human.

38. The method of claim 33, wherein said area of skin is in an armpit of the human.

39. The method of claim 33, wherein said area of skin is on the torso of the human.

40. The method of claim 1, wherein the composition is applied to an area of skin of a woman with hirsutism.

41. The method of claim 1, wherein said hair growth comprises androgen stimulated hair growth.

42. The method of claim 1, wherein the composition further includes a second component that also causes a reduction in hair growth.

43. A method of reducing mammalian hair growth, which comprises

selecting an area of skin including hair follicles from which reduced hair growth is desired; and

applying to the skin a compound selected from the group consisting of prostaglandin D_2, analogs of prostaglandin D_2, PGJ_2, or an analog of PGJ_2, in an amount effective to reduce hair growth.

44. A method of reducing mammalian hair growth, which comprises

selecting an area of skin including hair follicles from which reduced hair growth is desired; and

applying to the skin a compound that activates DP receptor signal transduction pathway in an amount effective to reduce hair growth.

45. A method of reducing mammalian hair growth, which comprises

selecting an area of skin including hair follicles from which reduced hair growth is desired; and

applying to the skin a compound that inactivates prostaglandin D_2 metabolic pathway in an amount effective to reduce hair growth.